10-Q: Cibus Narrows Focus to Rice, Raises Capital Amid Losses

Cibus, Inc. reported increased revenue and reduced operating cash burn in Q2 2025, driven by strategic streamlining and capital raises, despite a significant net loss and goodwill impairment.

Summary

• Net loss attributable to Cibus, Inc. stockholders increased to $72.258 million for the six months ended June 30, 2025, compared to $48.318 million for the same period in 2024.
• Revenue for the six months ended June 30, 2025, increased by 42% to $1.967 million, up from $1.383 million in the prior year.
• Cash and cash equivalents rose to $36.463 million as of June 30, 2025, from $14.433 million at December 31, 2024, primarily due to capital raises.
• Cash used in operating activities decreased by 17% to $25.431 million for the six months ended June 30, 2025, compared to $30.528 million in the prior year, reflecting cost reduction initiatives.
• The company recorded a goodwill impairment of $20.950 million for the six months ended June 30, 2025.
• A restructuring initiative in Q4 2024 and further streamlining in June 2025 aim to reduce annual net cash usage to approximately $30.0 million by 2026.
• The company raised approximately $21.4 million in net proceeds from a January 2025 registered direct offering and $25.0 million from a June 2025 SEC-registered public offering.
• An estimated $3.0 million litigation liability was accrued due to an unexpected Ninth Circuit Court of Appeals decision.

Sentiment

Score: 4

Explanation: While there are positive operational and regulatory advancements, and cash burn is being managed, the significant net loss, goodwill impairment, and explicit 'going concern' warning indicate substantial financial challenges and a high need for further capital, outweighing the positive developments.

Positives

• Revenue increased by 42% to $1.967 million for the six months ended June 30, 2025, driven by collaboration agreements for Rice and Sustainable Ingredients.
• Cash used in operating activities decreased by 17% to $25.431 million for the six months ended June 30, 2025, indicating improved operational efficiency and cost control.
• Successful capital raises in January and June 2025 provided approximately $46.4 million in net proceeds, significantly increasing cash and cash equivalents.
• Achieved key regulatory validations for RTDS technologies in the United States (USDA-APHIS for Canola) and Ecuador (HT1 and HT3 Rice traits equivalent to conventional breeding).
• EU member states endorsed the negotiating mandate on New Genomic Techniques (NGTs) regulation, potentially opening a large market.
• Established production standards for RTDS gene editing in Rice and Canola, capable of editing and returning customer elite germplasm within 12-15 months.
• Signed a new collaboration agreement with Semillano, a Colombian Rice seed company, to advance commercialization of Rice herbicide tolerance traits in Latin America.
• Successfully edited Soybean cells for the HT2 trait, enabling expanded platform development.
• Achieved a milestone in the Rice platform with field trial results for stacked gene-edited herbicide tolerance traits, a first for Rice weed management.

Negatives

• Net loss attributable to Cibus, Inc. stockholders increased by 50% to $72.258 million for the six months ended June 30, 2025, compared to $48.318 million in the prior year.
• A goodwill impairment charge of $20.950 million was recognized for the six months ended June 30, 2025, reflecting a decline in the company's stock price.
• The company has incurred losses since its inception and anticipates continued losses for the next several years, raising substantial doubt about its ability to continue as a going concern.
• An unplanned current liability of $3.0 million was accrued for litigation, representing a potential repayment of insurance coverage proceeds.
• Selling, general, and administrative expenses increased by 1% to $16.507 million for the six months ended June 30, 2025, primarily due to the litigation liability.
• Other interest income, net, decreased by 38% due to lower cash balances in the prior period.

Risks

• The company needs additional near-term funding to finance its activities and may face challenges in obtaining additional capital on acceptable terms, or at all.
• Changes in expected or existing competition could adversely affect the company's market position and profitability.
• Challenges to the company's intellectual property protection and unexpected costs associated with defending intellectual property rights pose significant risks.
• Increased or unanticipated time and resources may be required for the company's development efforts for its priority opportunities in Rice and biofragrance products and sustainable ingredients.
• Reliance on third parties for development activities and commercialization introduces dependencies and potential delays.
• Challenges associated with the company's ability to effectively license its productivity traits and sustainable ingredient products could limit revenue generation.
• There is a risk that farmers may not recognize the value in germplasm containing the company's traits or that farmers and processors fail to work effectively with crops containing these traits.
• Delays or disruptions in the company's platform or trait product development efforts could impact commercialization timelines.
• The inability to identify partners to fund the company's non-Rice productivity trait portfolio could limit the development of these traits.
• Challenges may arise in respect of the company's production of high-quality plants and seeds cost-effectively on a large scale.
• The company's dependence on distributions from Cibus Global to pay taxes and cover its corporate and overhead expenses creates financial vulnerability.
• Regulatory developments that disfavor or impose significant burdens on gene editing processes or products, including delays and uncertainties regarding regulatory developments in the European Union, could hinder market access.
• The company's ability to achieve commercial success is uncertain.
• Commodity prices and other market risks facing the agricultural sector could impact demand for the company's products.
• Technological developments could render the company's technologies obsolete.
• Impacts of headcount reductions and other cost reduction measures, including operational and strategic challenges, loss of institutional knowledge, unplanned attrition, and reduced employee morale, may adversely affect operations.
• Changes in macroeconomic and market conditions, including inflation, supply chain constraints, rising interest rates, economic volatility, and dynamic trade policies, could negatively affect the business.
• Dislocations in the capital markets and challenges in accessing liquidity could impact the company's ability to execute its business plan.
• The company's assessment of the period of time through which its financial resources will be adequate to support operations is a forward-looking statement and may prove to be wrong, potentially shortening its cash runway.
• An unexpected $3.0 million litigation liability has created an unplanned current liability, further impacting cash resources.

Future Outlook

The company anticipates continued net losses for the next several years but expects to reduce its annual net cash usage to approximately $30.0 million by 2026 through ongoing cost reduction initiatives. Commercial launches of Rice herbicide tolerance traits are targeted for Latin America in 2027 and the United States in 2028. The sustainable ingredients program is expected to generate nominal revenues in 2025 with commercial expansion planned for 2026. The company believes its existing cash and cash equivalents are sufficient to fund operations into the second quarter of 2026 but will need to raise additional capital to continue as a going concern beyond that period.

Management Comments

• "The first half of 2025 has marked significant progress across Cibus' key platforms and initiatives and saw key regulatory validation of Cibus RTDS technologies in the United States and Ecuador."
• "The Company believes its Rice herbicide tolerance traits represent potential annual accessible royalties of over $200 million upon full commercialization across target markets."
• "Cibus time bound and predictable approach to trait development is continuing to resonate strongly with customers and partners alike, attracting commercial interest across its platforms."
• "Cibus is positioned at an important inflection point in the agricultural industry with regulatory progress advancing globally, the Companys Rice traits moving into customer germplasm, and its disease resistance program showing remarkable results."
• "The Company anticipates that the cost reduction actions announced to date, including rationalizing human capital resources and certain non-core facilities, have the potential to reduce the Companys annual net cash usage to approximately $30.0 million by 2026, which is expected to contribute to improved cash flow and financial stability."

Industry Context

Cibus operates in the agricultural biotechnology sector, focusing on gene editing to develop plant traits. The industry is experiencing a shift towards gene-edited traits, which are distinguishable from GMOs and face fewer regulatory hurdles in key markets like the US and parts of Latin America. The EU's progress on New Genomic Techniques (NGTs) regulation signals a potential opening of a significant market, aligning with Cibus' non-transgenic approach. The company's focus on herbicide tolerance in Rice addresses a critical need for improved weed management in major agricultural food crops, a long-standing challenge for farmers globally. The development of bio-based biofragrance products and sustainable ingredients also taps into growing consumer demand for environmentally friendly solutions.

Comparison to Industry Standards

• Cibus' RTDS platform's capability to edit and return customer elite germplasm with specific edits within 12 to 15 months is a competitive advantage in terms of speed and efficiency compared to traditional breeding methods or even some other gene-editing approaches.
• The successful field trial results for stacked gene-edited herbicide tolerance traits in Rice represent a significant advancement, potentially positioning Cibus as a leader in this specific application, as it is noted as the 'first known trial' of its kind.
• The regulatory approvals in the United States (USDA-APHIS) and Ecuador, classifying Cibus' gene-edited traits as equivalent to conventionally bred crops and not subject to heightened GMO regulation, align with a growing global trend of favorable regulatory treatment for precision gene editing, differentiating it from companies reliant on transgenic GMO technologies that face stricter regulations (e.g., in the EU).

Management Changes

Legal Proceedings

• The company has accrued an estimated $3.0 million for litigation liability based on an unexpected decision from the Ninth Circuit Court of Appeals, representing a potential repayment of insurance coverage proceeds previously awarded.

Related Party Transactions

• Royalty liability related parties: The company has an arrangement to pay future royalty payments to certain investors, including directors and affiliated entities, based on 10% of actual Subject Revenues collected. The liability balance was $216.487 million as of June 30, 2025, with interest expense of $17.045 million for the six months ended June 30, 2025.
• Mr. Riggs, a director, was issued 5,714,286 shares of Class A Common Stock in the June 2025 SEC-Registered Public Offering.
• The Warrant Amendment Agreement, which reduced the exercise price and extended the termination date of certain 2024 Common Warrants, was conditioned on stockholder approval for Mr. Riggs' warrants, which occurred on May 22, 2025.

Stakeholder Impact

• **Shareholders**: Experienced significant dilution from recent capital raises (increased shares outstanding from 27,939,023 to 52,480,413 Class A shares from Dec 31, 2024, to June 30, 2025). Face substantial doubt about the company's ability to continue as a going concern and potential for further dilution from future capital raises. Goodwill impairment reflects a decline in valuation.
• **Employees**: Impacted by a reduction in workforce of approximately 34 full-time employees, leading to one-time charges for accrued vacation and severance payments. Remaining employees may face operational and strategic challenges, potential loss of morale, and increased workload due to streamlining.
• **Customers/Partners**: Benefit from continued advancement of RTDS technology and specific trait development (e.g., Rice herbicide tolerance, sustainable ingredients). New collaboration with Semillano indicates positive engagement. However, the company's financial instability could pose long-term risks to product development and delivery.
• **Creditors**: The company's 'going concern' warning and need for additional capital may increase perceived credit risk, potentially affecting future borrowing terms.
• **Regulatory Bodies**: Continued engagement with and positive determinations from USDA-APHIS, California Rice Commission, and Ecuador's Ministry of Agriculture and Livestock demonstrate compliance and validation of gene-editing technologies.

Next Steps

• Complete the implementation of streamlined operational focus and related cost reduction actions over the remainder of 2025.
• Continue to advance the commercialization of weed management traits for Rice, targeting initial launches in Latin America in 2027 and the United States in 2028.
• Continue to meet development milestones for partner-funded bio-based fermentation biofragrance products and sustainable ingredients, with targeted commercial expansion in 2026.
• Opportunistically pursue partner-funded projects for the remainder of its productivity trait portfolio.
• Management will need to raise additional capital to support its business plans to continue as a going concern within one year after the date of issuance of these financial statements.
• The company is evaluating the impact of the One Big Beautiful Bill Act (OBBBA) on its financial statements, with changes to be included beginning in Q3 2025.
• The company continues to evaluate its options in respect of the Ninth Circuit Court of Appeals decision regarding the $3.0 million litigation liability.

Key Dates

Recommendation

Despite some operational progress and successful capital raises, the company faces severe financial distress, evidenced by a substantial net loss, significant goodwill impairment, and an explicit 'going concern' warning. The need for continuous capital raises, coupled with ongoing losses and the risk of further dilution, presents a highly unfavorable investment profile. While cost-cutting measures are in place, their sufficiency to achieve long-term viability is uncertain. The stock carries significant risk of further decline due to fundamental financial instability and the high probability of future dilutive financing events.

Keywords

Gene Editing, Agricultural Biotechnology, Plant Traits, Rice Herbicide Tolerance, RTDS, Rapid Trait Development System, Sustainable Ingredients, Crop Yields, Weed Management, SEC Filing, 10-Q, Financial Results, Capital Raise, Restructuring, Goodwill Impairment, Going Concern, NASDAQ, CBUS